Morgan Stanley raised the firm’s price target on Globus Medical (GMED) to $83 from $74 and keeps an Equal Weight rating on the shares. The company reported “solid” Q3 topline and bottom-line beats, notes the analyst, who raised the firm’s FY24 and FY25 revenue and EPS estimates to $2.5B and $2.98 and $2.8B and $3.35, respectively.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Globus Medical price target raised to $92 from $80 at Stifel
- Morning Movers: CVS Health surges and ODP sinks following Q3 results
- Globus Medical price target raised to $92 from $80 at RBC Capital
- Globus Medical price target raised to $100 from $93 at Barclays
- Globus Medical price target raised to $85 from $70 at Canaccord